Phenylketonuria Treatment Market (Product Type - Dietary Supplement, and Drugs; Route of Administration - Oral, and Parenteral; Distribution Channel - Hospital Pharmacies, Online Pharmacies, Pediatric Clinics, and Drug Stores): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

A recent report published by Infinium Global Research on phenylketonuria treatment market provides in-depth analysis of segments and sub-segments in the global as well as regional phenylketonuria treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional phenylketonuria treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global phenylketonuria treatment market. According to the report, the global phenylketonuria treatment market is projected to grow at a healthy CAGR over the forecast period of 2019-2025.

Market Insight

Phenylketonuria (PKU) is an inborn error of metabolism in which levels of phenylalanine are increases in blood. PKU is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine. It is detected during the first day of life with the appropriate blood test. Phenylketonuria may cause intellectual disability, seizures, behavior problems and delayed development and other health problems. Additionally, it may also lead to a musty smell and lighter skin. Treatment for phenylketonuria is to keep plasma phenylalanine levels within 120-360 µmol/L. This is generally achieved by the appropriate diet plan.

Increasing prevalence of phenylketonuria across the globe is the major factor driving the growth of Phenylketonuria market. Moreover, growth in research and development of novel drugs for Phenylketonuria treatment is also another factor augmenting the market growth. Additionally, the introduction of new gene therapy, for the treatment of PKU and growing awareness about PKU is estimated to further enhance the market growth. However, the high cost of treatment and strict government regulation are anticipated to hamper the growth of the market. As per the National organization of rare disorders, it is reported an incidence of PKU from newborn screening programs ranges from one in 13,500 to 19,000 newborns in the United States. The severity of phenylketonuria is uncommon in the U.S., owing to the early screening and availability of improved treatment soon after birth. Which in turns, hampering the growth in U.S. region. Furthermore, an increase in merger and acquisition, collaborations among key manufacturers are anticipated to creates growth opportunities for the phenylketonuria treatment market in the coming years.

Among the regions, North America is anticipated to hold maximum share in phenylketonuria treatment market. The growth is attributed due to highly developed infrastructures and high awareness regarding early treatment of phenylketonuria. Moreover, initiatives taken by governments for the treatment of phenylketonuria, technological advancement, and the presence of leading manufacturers are some supporting factors responsible for market growth. Furthermore, Asia Pacific is expected to witness significant CAGR during the forecast period owing to an increase in R & D activities for the development of drugs for phenylketonuria and growth in healthcare expenditures.

Segment Covered

The report on global phenylketonuria treatment market covers segments such as product type, route of administration, and distribution channel. On the basis of product type, the sub-markets include dietary supplement, and drugs. On the basis of route of administration, the sub-markets include oral, and parenteral. On the basis of distribution channel, the sub-markets include hospital pharmacies, online pharmacies, pediatric clinics, and drug stores.

Companies Profiled:

The report provides profiles of the companies in the market such as Erytech Pharma, Daiichi Sankyo Company, Limited, SOM Innovation Biotech, S.L., Codexis, Inc., Synthetic Biologics, Inc., American Gene Technologies International Inc, Dimension Therapeutics, Inc, BioMarin Pharmaceutical Inc., Cambrooke Therapeutics, Inc., and Danone.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of phenylketonuria treatment market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.